Apolipoprotein(a) size polymorphism is associated with coronary heart disease in polygenic hypercholesterolemia

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 14, Issue 4, 2004, Pages 193-199

  Emanuele, E ^a   Peros, E ^a   Minoretti, P ^a   D'Angelo, A ^a   Piccinni, M N ^a   Montagna, L ^a   Geroldi, D ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Apolipoprotein(a); Coronary heart disease; Genetic markers; Lipoprotein(a); Polygenic hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PHENOTYPE; PREDICTION; PREVALENCE; SMOKING; STATISTICAL SIGNIFICANCE;

EID: 7744225871     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-4753(04)80004-8     Document Type: Article

References (38)

1. Thompson GR (1990) Primary hyperlipidaemia. Br Med Bull 46: 986-1004
2. Ross R (1986) The pathogenesis of atherosclerosis: an update. N Engl J Med 314: 488-500
3. Castelli WP (1984) Epidemiology of coronary heart disease: The Framingham Study. Am J Med 76: 4-12
4. Neaton JD, Blackburn H, Jacobs D (1992) Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 152: 1490-1500
5. Brown BG, Zhao XQ, Chait A, et al (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583-1592
6. Grundy SM (1998) Statin trials and goals of cholesterol-lowering therapy. Circulation 97: 1436-1439
7. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22
8. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM (1986) Association of levels of lipoprotein(a), plasma lipid and other lipoprotein with coronary heart disease documented by angiography. Circulation 74: 758-765
9. Hearn JA, DeMaio SJ Jr, Roubin GS, Hammarstrom M, Sgoutas D (1990) Predictive value of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol 66: 1176-1180
10. McLean JW, Tomlinson JE, Kuang WJ, et al (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330: 132-137
11. Scanu AM, Fless GM (1990) Lipoprotein (a): Heterogeneity and biological relevance. J Clin Invest 85: 1709-1715
12. Kamboh MI, Ferrel RE, Kottke BA (1991) Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 49: 1063-1074
13. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ (1993) Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 191: 1192-1196
14. Gazzaruso C, Garzaniti A, Buscaglia P, et al (1999) Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. J Am Coll Cardiol 33:157-163
15. Sandholzer C, Saha N, Kark JD, et al (1992) Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 12: 1214-1226
16. Kraft HG, Lingenhel A, Kochl S, et al (1996) Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 16: 713-719
17. Hiraga T, Okubo M, Kobayashi T, Nakanishi K, Sugimoto T, Murase T (1993) Serum lipoprotein(a) levels differ in different phenotypes of primary hyperlipoproteinemia. Metabolism 42:1327-1330
18. Cicero AF, Panourgia MP, Linarello S, D'Addato S, Sangiorgi Z, Gaddi A (2003) Serum lipopotein (a) levels in a large sample of subjects affected by familial combined hyperlipoproteinaemia and in general population. J Cardiovasc Risk 10: 149-151
19. Mbewu AD, Bhatnagar D, Durrington PN, et al (1991) Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 11: 940-946
20. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G (2000) Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 20: 522-528
21. Ritter MM, Geiss HC, Richter WO, Schwandt P (1994) Lipoprotein(a) concentrations and phenotypes in controls and patients with hypercholesterolemia or hypertriglyceridemia. Metabolism 43: 572-578
22. Tato F, Keller C, Schuster H, Spengel F, Wolfram G, Zollner N (1993) Relation of lipoprotein(a) to coronary heart disease and duplex sonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis 101: 69-77
23. Bowden JF, Pritchard PH, Hill JS, Frohlich JJ (1994) Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 14: 1561-1568
24. Steering Committee of the Simon Broome Register Group (1992) Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br Med J 303: 893-896
25. Porkka KV, Nuotio I, Pajukanta P, et al (1997) Phenotype expression in familial combined hyperlipidemia. Atherosclerosis 133: 245-253
26. World Health Organization (1985) Diabetes Mellitus: Report of a WHO Study Group. Geneva: World Health Organization. Tech Rep Ser. No. 727
27. Falcone C, de Servi S, Poma E, et al (1987) Clinical significance of exercise-induced silent myocardial ischemia in patients with coronary artery disease. J Am Coll Cardiol 9: 295-299
28. Gazzaruso C, Buscaglia P, Garzaniti A, et al (1996) Lipoprotein(a) plasma concentrations, apolipoprotein (a) polymorphism and family history of coronary heart disease in patients with essential hypertension. J Cardiovasc Risk 3: 191-197
29. Geroldi D, Bellotti V, Buscaglia P, et al (1993) Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta 221: 159-169
30. Gazzaruso C, Garzaniti A, Buscaglia P, et al (1998) Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. J Cardiovasc Risk 5: 37-42
31. Shen XS, Mymin D, Dembinski T, Krahn A, Angel A (1995) Polymorphism and peripheral levels of apolipoprotein(a) in polygenic hypercholesterolemia and combined hyperlipidemia. Clin Invest Med 18: 33-41
32. Knight BL, Perombelon YF, Soutar AK, Wade DP, Seed M (1991) Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 87: 227-237
33. Watts GF, Kearney EM, Taub NA, Slavin BM (1993) Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with polygenic hypercholesterolaemia. J Clin Pathol 46: 267-270
34. Scott J (1991) Lipoprotein(a). Thrombotic and atherogenic. Br Med J 303: 663-664
35. Angles-Cano E, Rojas G (2002) Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site. Biol Chem 383: 93-99
36. Angles-Cano E, de la Pena Diaz A, Loyau S (2001) Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 936: 261-275
37. Valenti K, Aveynier E, Laporte F, Hadjian AJ (1997) Evaluation of the genotyping and phenotyping approaches in the investigation of apolipoprotein (a) size polymorphism. Clin Chim Acta 263: 249-260
38. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H (1996) Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 12: 2569-2585